Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals, Inc. is trading at $50.00, down 0.04% on the session. The 50 day average sits at $56.44 and the 200 day at $34.31, which puts the stock in a uptrend. RSI is at 38.4, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $48.79 with resistance near $57.00, so that band frames the current range. Average daily movement is roughly $3.06, or about 6.1% of the share price, which is what any stop placement has to allow for. The overall health score of 43 out of 100 combines a trend score of 61, momentum of 25 and a risk score of 40.

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.